BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 17090654)

  • 1. Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates.
    Nathwani AC; Gray JT; McIntosh J; Ng CY; Zhou J; Spence Y; Cochrane M; Gray E; Tuddenham EG; Davidoff AM
    Blood; 2007 Feb; 109(4):1414-21. PubMed ID: 17090654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins.
    Nathwani AC; Rosales C; McIntosh J; Rastegarlari G; Nathwani D; Raj D; Nawathe S; Waddington SN; Bronson R; Jackson S; Donahue RE; High KA; Mingozzi F; Ng CY; Zhou J; Spence Y; McCarville MB; Valentine M; Allay J; Coleman J; Sleep S; Gray JT; Nienhuis AW; Davidoff AM
    Mol Ther; 2011 May; 19(5):876-85. PubMed ID: 21245849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver.
    Nathwani AC; Gray JT; Ng CY; Zhou J; Spence Y; Waddington SN; Tuddenham EG; Kemball-Cook G; McIntosh J; Boon-Spijker M; Mertens K; Davidoff AM
    Blood; 2006 Apr; 107(7):2653-61. PubMed ID: 16322469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stable human FIX expression after 0.9G intrauterine gene transfer of self-complementary adeno-associated viral vector 5 and 8 in macaques.
    Mattar CN; Nathwani AC; Waddington SN; Dighe N; Kaeppel C; Nowrouzi A; Mcintosh J; Johana NB; Ogden B; Fisk NM; Davidoff AM; David A; Peebles D; Valentine MB; Appelt JU; von Kalle C; Schmidt M; Biswas A; Choolani M; Chan JK
    Mol Ther; 2011 Nov; 19(11):1950-60. PubMed ID: 21629224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimized human factor IX expression cassettes for hepatic-directed gene therapy of hemophilia B.
    Zhang R; Wang Q; Zhang L; Chen S
    Front Med; 2015 Mar; 9(1):90-9. PubMed ID: 25663062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial.
    Monahan PE; Sun J; Gui T; Hu G; Hannah WB; Wichlan DG; Wu Z; Grieger JC; Li C; Suwanmanee T; Stafford DW; Booth CJ; Samulski JJ; Kafri T; McPhee SW; Samulski RJ
    Hum Gene Ther; 2015 Feb; 26(2):69-81. PubMed ID: 25419787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy.
    Grimm D; Zhou S; Nakai H; Thomas CE; Storm TA; Fuess S; Matsushita T; Allen J; Surosky R; Lochrie M; Meuse L; McClelland A; Colosi P; Kay MA
    Blood; 2003 Oct; 102(7):2412-9. PubMed ID: 12791653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy.
    Jiang H; Couto LB; Patarroyo-White S; Liu T; Nagy D; Vargas JA; Zhou S; Scallan CD; Sommer J; Vijay S; Mingozzi F; High KA; Pierce GF
    Blood; 2006 Nov; 108(10):3321-8. PubMed ID: 16868252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B.
    Nathwani AC; Tuddenham EG; Rangarajan S; Rosales C; McIntosh J; Linch DC; Chowdary P; Riddell A; Pie AJ; Harrington C; O'Beirne J; Smith K; Pasi J; Glader B; Rustagi P; Ng CY; Kay MA; Zhou J; Spence Y; Morton CL; Allay J; Coleman J; Sleep S; Cunningham JM; Srivastava D; Basner-Tschakarjan E; Mingozzi F; High KA; Gray JT; Reiss UM; Nienhuis AW; Davidoff AM
    N Engl J Med; 2011 Dec; 365(25):2357-65. PubMed ID: 22149959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancing transduction of the liver by adeno-associated viral vectors.
    Nathwani AC; Cochrane M; McIntosh J; Ng CY; Zhou J; Gray JT; Davidoff AM
    Gene Ther; 2009 Jan; 16(1):60-9. PubMed ID: 18701909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimization of self-complementary AAV vectors for liver-directed expression results in sustained correction of hemophilia B at low vector dose.
    Wu Z; Sun J; Zhang T; Yin C; Yin F; Van Dyke T; Samulski RJ; Monahan PE
    Mol Ther; 2008 Feb; 16(2):280-9. PubMed ID: 18059373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a Clinical Candidate AAV3 Vector for Gene Therapy of Hemophilia B.
    Brown HC; Doering CB; Herzog RW; Ling C; Markusic DM; Spencer HT; Srivastava A; Srivastava A
    Hum Gene Ther; 2020 Oct; 31(19-20):1114-1123. PubMed ID: 32657150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous administration of an AAV-2 vector for the expression of factor IX in mice and a dog model of hemophilia B.
    Harding TC; Koprivnikar KE; Tu GH; Zayek N; Lew S; Subramanian A; Sivakumaran A; Frey D; Ho K; VanRoey MJ; Nichols TC; Bellinger DA; Yendluri S; Waugh J; McArthur J; Veres G; Donahue BA
    Gene Ther; 2004 Jan; 11(2):204-13. PubMed ID: 14712305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene therapy for hemophilia B mice with scAAV8-LP1-hFIX.
    Lu W; Zhou Q; Yang H; Wang H; Gu Y; Shen Q; Xue J; Dong X; Chen J
    Front Med; 2016 Jun; 10(2):212-8. PubMed ID: 27052253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Term Follow-Up of the First in Human Intravascular Delivery of AAV for Gene Transfer: AAV2-hFIX16 for Severe Hemophilia B.
    George LA; Ragni MV; Rasko JEJ; Raffini LJ; Samelson-Jones BJ; Ozelo M; Hazbon M; Runowski AR; Wellman JA; Wachtel K; Chen Y; Anguela XM; Kuranda K; Mingozzi F; High KA
    Mol Ther; 2020 Sep; 28(9):2073-2082. PubMed ID: 32559433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors influencing in vivo transduction by recombinant adeno-associated viral vectors expressing the human factor IX cDNA.
    Nathwani AC; Davidoff A; Hanawa H; Zhou JF; Vanin EF; Nienhuis AW
    Blood; 2001 Mar; 97(5):1258-65. PubMed ID: 11222368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of adeno-associated viral vectors based on serotype 8 and 9 vs. lentiviral vectors for hemophilia B gene therapy.
    Vandendriessche T; Thorrez L; Acosta-Sanchez A; Petrus I; Wang L; Ma L; DE Waele L; Iwasaki Y; Gillijns V; Wilson JM; Collen D; Chuah MK
    J Thromb Haemost; 2007 Jan; 5(1):16-24. PubMed ID: 17002653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic expression of human clotting factors IX and X following adeno-associated viral vector-mediated intrauterine gene transfer in early-gestation fetal macaques.
    Chan JKY; Gil-Farina I; Johana N; Rosales C; Tan YW; Ceiler J; Mcintosh J; Ogden B; Waddington SN; Schmidt M; Biswas A; Choolani M; Nathwani AC; Mattar CNZ
    FASEB J; 2019 Mar; 33(3):3954-3967. PubMed ID: 30517034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In Utero Transfer of Adeno-Associated Viral Vectors Produces Long-Term Factor IX Levels in a Cynomolgus Macaque Model.
    Mattar CNZ; Gil-Farina I; Rosales C; Johana N; Tan YYW; McIntosh J; Kaeppel C; Waddington SN; Biswas A; Choolani M; Schmidt M; Nathwani AC; Chan JKY
    Mol Ther; 2017 Aug; 25(8):1843-1853. PubMed ID: 28462816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modified infusion procedures affect recombinant adeno-associated virus vector type 2 transduction in the liver.
    Ohashi K; Nakai H; Couto LB; Kay MA
    Hum Gene Ther; 2005 Mar; 16(3):299-306. PubMed ID: 15812225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.